X
[{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Elixiron Immunotherapeutics"},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Pangu Capital","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Elixiron Immunotherapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .
Lead Product(s):
EI-1071
Therapeutic Area: Neurology
Product Name: EI-1071
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Pangu Capital
Deal Size: $27.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
August 23, 2021
Details:
Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.
Lead Product(s):
EI1071
Therapeutic Area: Neurology
Product Name: EI1071
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Alzheimer's Association
Deal Size: $1.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
August 26, 2020